Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David A. Hyman, MD, JD, on Inclusive Shared Savings

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Sep
14
Today In Oncology
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
Extended-Interval Dosing of Tarlatamab Found Safe Effective in SCLC
Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo